ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACTUATE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.60−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $14.30M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
56.3%
14M of 24M shares
Institutional holders
64
18 new, 14 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $1.62M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Voss Capital, LP | 1,814,263 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| Cocke Travis W. | 1,227,756 | 5.30% | 13G (passive) | Dec 15, 2025 |
| Aaron G.L. Fletcher | 10,267,232 | 49.80% | 13D (active) amendment | Jun 27, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACTU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 10,049,996 | 41.85% | $15.38M | – | 36.90% |
| Voss Capital, LLC | 1,725,000 | 7.18% | $2.64M | – | 0.12% |
| Vanguard Capital Management LLC | 393,433 | 1.64% | $601.95K | −7,096 | 0.00% |
| Aqr Capital Management LLC | 127,493 | 0.53% | $195.06K | +100,384 | 0.00% |
| Geode Capital Management, LLC | 112,554 | 0.47% | $172.21K | −115,777 | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 102,612 | 0.43% | $157.00K | +8,020 | 0.01% |
| Palogic Value Management, L.P. | 100,000 | 0.42% | $153.00K | – | 0.05% |
| Millennium Management LLC | 96,684 | 0.40% | $147.93K | New | 0.00% |
| BlackRock, Inc. | 90,035 | 0.37% | $137.75K | −337,118 | 0.00% |
| ABS Investment Management LLC | 73,186 | 0.30% | $111.98K | New | 0.07% |
| ABS Direct Equity Fund LLC | 73,186 | 0.30% | $111.98K | +23,186 | 0.07% |
| Vanguard Fiduciary Trust Co | 54,497 | 0.23% | $83.38K | −8,095 | 0.00% |
| Rock Creek Group, LP | 39,263 | 0.16% | $60.07K | – | 0.01% |
| Jane Street Group, LLC | 39,132 | 0.16% | $59.87K | New | 0.00% |
| HighTower Advisors, LLC | 36,461 | 0.15% | $55.79K | New | 0.00% |
| Goldman Sachs Group Inc | 35,498 | 0.15% | $54.31K | +23,090 | 0.00% |
| Sfmg, LLC | 33,000 | 0.14% | $50.49K | – | 0.00% |
| Susquehanna International Group, Llp | 28,182 | 0.12% | $43.12K | New | 0.00% |
| Bridgeway Capital Management, LLC | 23,482 | 0.10% | $35.93K | −7,500 | 0.00% |
| State Street Corp | 21,850 | 0.09% | $33.43K | −44,180 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 64 | 14M | 56.3% | 18 / 18 | 20 / 14 | 1M | 1M |
| Q1 2026 | 61 | 14M | 57.7% | 22 / 20 | 10 / 4 | 1M | 0M |
| Q4 2025 | 45 | 13M | 54.6% | 8 / 21 | 9 / 6 | 1M | 0M |
| Q3 2025 | 43 | 12M | 50.1% | 7 / 17 | 11 / 2 | 1M | 0M |
| Q2 2025 | 38 | 11M | 46.7% | 21 / 12 | 2 / 8 | 1M | 0M |
| Q1 2025 | 25 | 10M | 43.3% | 9 / 10 | 1 / 3 | 0M | 0M |
| Q4 2024 | 19 | 10M | 42.1% | 13 / 1 | 2 / 4 | 10M | 0M |
| Q3 2024 | 10 | 0M | 1.6% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ACTU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 287,385 | 1.20% | $439.70K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 106,048 | 0.44% | $162.25K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 51,919 | 0.22% | $104.88K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 48,395 | 0.20% | $97.76K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 38,230 | 0.16% | $58.49K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 23,482 | 0.10% | $35.93K | 0.02% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 15,885 | 0.07% | $32.09K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 13,591 | 0.06% | $27.45K | 0.00% | May 31, 2026 |
| iShares Russell 2000 ETF | 13,249 | 0.06% | $20.27K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 12,252 | 0.05% | $24.75K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 8,845 | 0.04% | $17.87K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 5,506 | 0.02% | $8.42K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 5,490 | 0.02% | $11.09K | 0.00% | May 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 1,738 | 0.01% | $2.66K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,700 | 0.01% | $2.60K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel M. Schmitt | President, CEO and Director | 1,052,977 | 4.38% | Aug 14, 2026 |
| Andrew Paul Mazar | Chief Operating Officer | 127,250 | 0.53% | Apr 1, 2026 |
| Paul J. Lytle | Chief Financial Officer | – | – | Apr 1, 2026 |
| Martin H. Huber Jr. | Director | – | – | May 22, 2026 |
| Amy L. Ronneberg | Director | – | – | May 22, 2026 |
| Roger Sawhney | Director | – | – | May 22, 2026 |
| Jason A. Keyes | Director | – | – | May 22, 2026 |
| Todd S. Thomson | Director, 10% owner | 2,354,344 | 9.80% | May 22, 2026 |
| Aaron G.L. Fletcher | Director, 10% owner | – | – | May 22, 2026 |
| Dan Zabrowski | Director | 76,348 | 0.32% | May 22, 2026 |
| Kairos Venture Partners II, L.P. | Director, 10% owner | – | – | Jan 7, 2026 |
| BIOS Advisors GP, LLC | Director, 10% owner | – | – | Jun 30, 2025 |
| BIOS Fund II QP, LP | Director, 10% owner | 9,147,214 | 38.09% | Jun 30, 2025 |
| BIOS Fund II NT, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| BIOS Equity Partners III, LP | Director, 10% owner | 9,895,975 | 41.21% | Jun 30, 2025 |
| BIOS Fund III, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| BIOS Fund III QP, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| BIOS Fund III NT, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| Bios Equity COF, LP | Director, 10% owner | 10,196,456 | 42.46% | Jun 30, 2025 |
| Bios Clinical Opportunity Fund, LP | Director, 10% owner | 1,472,797 | 6.13% | Jun 30, 2025 |
| BIOS Actuate Co-Invest II, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| Bios Actuate Co-Invest III, LP | Director, 10% owner | 231,377 | 0.96% | Jun 30, 2025 |
| BIOS Actuate Co-Invest I, LP | Director, 10% owner | 10,196,456 | 42.46% | Jun 30, 2025 |
| Bios 2024 Co-Invest, LP | Director, 10% owner | 125,000 | 0.52% | Jun 30, 2025 |
| Leslie W. Kreis | Director, 10% owner | – | – | Jun 30, 2025 |
| Cavu Management, LP | Director, 10% owner | 231,377 | 0.96% | Jun 30, 2025 |
| Cavu Advisors, LLC | Director, 10% owner | – | – | Jun 30, 2025 |
| BP Directors, LP | Director, 10% owner | 9,317,794 | 38.80% | Jun 30, 2025 |
| BIOS Fund I, LP | Director, 10% owner | – | – | Jun 30, 2025 |
| Bios Equity Partners II, LP | Director, 10% owner | – | – | Jun 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daniel M. Schmitt President, CEO and Director | Aug 14, 2026 | Option exercise | +272,056 | – | – | 422,237 |
| Daniel M. Schmitt President, CEO and Director | Aug 14, 2026 | Tax withholding | −120,521 | $1.01 | $121.73K | 301,716 |
| Daniel M. Schmitt President, CEO and Director | Feb 13, 2026 | Option exercise | +272,055 | – | – | 272,055 |
| Daniel M. Schmitt President, CEO and Director | Feb 13, 2026 | Tax withholding | −121,874 | $4.33 | $527.71K | 150,181 |
| Todd S. Thomson Director, 10% owner | Jan 5, 2026 | Sale | −280,000 | $5.80 | $1.62M | 904,795 |
| Bios Equity COF, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Actuate Co-Invest I, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Fund II, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Sale | −18,750 | $8.00 | $150.00K | 1,184,795 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Option exercise | +28,464 | $5.27 | $150.01K | 1,203,545 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +49,984 | – | – | 321,781 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +24,138 | – | – | 254,735 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +132,908 | – | – | 271,797 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +69,445 | – | – | 1,175,081 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +1,058,318 | – | – | 1,105,636 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +726,163 | – | – | 726,163 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +138,889 | – | – | 138,889 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +230,597 | – | – | 230,597 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +146,870 | – | – | 873,033 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Buy | +375,000 | $8.00 | $3.00M | 1,259,427 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +3,528 | $5.27 | $18.59K | 133,572 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $9.00 | $156.25K | 980,433 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +26,355 | $5.27 | $138.89K | 997,794 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $9.00 | $47.83K | 300,143 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +8,068 | $5.27 | $42.52K | 305,457 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +573,394 | – | – | 573,394 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +78,267 | – | – | 404,814 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +484,638 | – | – | 2,506,667 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +74,202 | – | – | 383,791 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +2,094,650 | – | – | 2,094,650 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +326,547 | – | – | 326,547 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +2,022,029 | – | – | 2,022,029 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +309,589 | – | – | 309,589 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +44,559 | – | – | 130,044 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +332,867 | – | – | 971,439 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +101,900 | – | – | 297,389 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +147,047 | – | – | 300,749 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +23,628 | – | – | 85,485 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +176,499 | – | – | 638,572 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +54,032 | – | – | 195,489 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +153,702 | – | – | 153,702 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +61,857 | – | – | 61,857 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +462,073 | – | – | 462,073 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +141,457 | – | – | 141,457 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +307,538 | – | – | 307,538 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +525,797 | – | – | 525,797 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Buy | +125,000 | $8.00 | $1.00M | 125,000 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $9.00 | $20.92K | 131,248 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +884,427 | – | – | 884,427 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 14, 2024 | Conversion | +61,857 | – | – | 61,857 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 14, 2024 | Conversion | +462,073 | – | – | 462,073 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kairos Venture Partners II, L.P. Affiliate | Dec 11, 2025 | 280,000 | $2.13M | Dec 11, 2025 | Private Investment, Pre-IPO |